Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. In the last several decades, its prevalence has increased, making it likely to be encountered in the primary care setting. The aim was to review the clinical presentation and diagnosis of NCFB, with an emphasis on the role of computed tomography (CT).
“Non-cystic Fibrosis Bronchiectasis Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-cystic Fibrosis Bronchiectasis Market.
The Non-cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
DelveInsight’s Non-cystic Fibrosis Bronchiectasis Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Non-cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:
• Colistimethate sodium: Zambon SpA
• Benralizumab: AstraZeneca
• Tobramycin Dry-powder Inhalation: Novartis
• CHF 6333: Chiesi Farmaceutici S.p.A
And Many Others
Further Non-cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-cystic Fibrosis Bronchiectasis therapies at: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Non-cystic Fibrosis Bronchiectasis Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Non-cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Non-cystic Fibrosis Bronchiectasis Treatment.
-
Non-cystic Fibrosis Bronchiectasis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Non-cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-cystic Fibrosis Bronchiectasis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF for Non-cystic Fibrosis Bronchiectasis Pipeline Report – https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Some of the key companies in the Non-cystic Fibrosis Bronchiectasis Therapeutics Market include:
Zambon SpA, AstraZeneca, Novartis, Chiesi Farmaceutici S.p.A, Insmed, SolAeroMed, Renovion, NovaBiotics, Chiesi Farmaceutici, CSL Behring, Arrowhead Pharmaceuticals and others.
Request for Sample PDF Report for Non-cystic Fibrosis Bronchiectasis Pipeline Assessment– https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Non-cystic Fibrosis Bronchiectasis Current Treatment Patterns
4. Non-cystic Fibrosis Bronchiectasis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Non-cystic Fibrosis Bronchiectasis Late Stage Products (Phase-III)
7. Non-cystic Fibrosis Bronchiectasis Mid-Stage Products (Phase-II)
8. Non-cystic Fibrosis Bronchiectasis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-cystic Fibrosis Bronchiectasis Discontinued Products
13. Non-cystic Fibrosis Bronchiectasis Product Profiles
14. Key Companies in the Non-cystic Fibrosis Bronchiectasis Market
15. Key Products in the Non-cystic Fibrosis Bronchiectasis Therapeutics Segment
16. Dormant and Discontinued Products
17. Non-cystic Fibrosis Bronchiectasis Unmet Needs
18. Non-cystic Fibrosis Bronchiectasis Future Perspectives
19. Non-cystic Fibrosis Bronchiectasis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report for Non-cystic Fibrosis Bronchiectasis Drugs and Therapies – https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
